Analysts predict Winrevair could solve half of the revenue p...

Analysts predict Winrevair could solve half of the revenue problem caused by Keytruda's loss of exclusivity. Its approval without serious safety warnings or restrictions is seen as a testament to Merck's strategic efforts.